2796 — Pharmarise Holdings Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesConservativeMicro CapValue Trap

Annual income statement for Pharmarise Holdings, fiscal year end - May 31st, JPY millions except per share, conversion factor applied.

	2020 May 31st	2021 May 31st	2022 May 31st	2023 May 31st	2024 May 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	JAS	JAS	JAS	JAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	51,030	52,324	51,608	52,030	54,466
Cost of Revenue
Gross Profit	7,438	8,068	8,117	8,134	8,449
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	50,258	51,446	50,306	50,969	54,257
Operating Profit	772	878	1,302	1,061	209
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	819	1,202	1,322	1,049	143
Provision for Income Taxes
Net Income After Taxes	581	420	458	347	-342
Minority Interest
Net Income Before Extraordinary Items
Net Income	578	426	448	333	-351
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	579	428	449	335	-351
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	111	110	104	97.6	63.3
Dividends per Share
Special Dividends per Share